Coronary artery disease (CAD) is influenced by genetic variation and traditional risk factors. Polygenic risk scores (PRS), which can be ascertained before the development of traditional risk factors, have been shown to identify individuals at elevated risk of CAD. Here, we demonstrate that a genome-wide PRS for CAD predicts all-cause mortality after accounting for not only traditional cardiovascular risk factors but also angiographic CAD itself.
C oronary artery disease (CAD) is a leading cause of death worldwide. Several comorbid conditions, including hypertension, hyperlipidemia, diabetes mellitus, and smoking contribute to the risk of developing CAD. Guidelines from the American College of Cardiology and American Heart Association for management of hyperlipidemia and hypertension recommend cardiovascular risk assessment based on these traditional risk factors to help clinicians identify individuals who may benefit from aggressive primary prevention strategies, and tools, including the Pooled Cohort Equation and scores derived from the Framingham Heart Study, have been developed to facilitate traditional risk factorbased assessment and stratification. [1] [2] [3] [4] [5] CAD is highly heritable, and recent large meta-analyses of genome-wide association studies have identified >150 genetic loci associated with CAD. 6, 7 Although the causal mechanisms underlying many of these genetic risk factors remain unclear, in total, they explain ≈30% of CAD heritability. [7] [8] [9] Polygenic risk scores (PRS), which sum the burden of genetic risk across the genome, have been proposed as a means of identifying individuals at elevated risk of CAD. For example, a PRS composed of 182 independent risk variants was found to be associated with elevated risk of early-onset CAD, and previous scores have been associated with angiographic extent of coronary obstruction and incident CAD. 10, 11 More recently, genome-wide PRS, which leverage millions of individual genetic variants to improve predictive power, have been associated with CAD in the UK BioBank population. [12] [13] [14] Because genetic risk is established before the clinical manifestations of traditional cardiovascular risk factors, PRS may provide early information for identifying individuals at elevated risk of CAD, as well as provide information that is complementary to traditional risk factors.
In addition to noninvasive assessment of traditional risk factors, coronary artery angiography is also an important tool for risk stratification-the angiographic burden of atherosclerosis is strongly associated with risk of subsequent cardiovascular events including myocardial infarction and death. 15 The presence of CAD by coronary angiography weighs heavily into risk management strategies. Individuals with known CAD receive aggressive preventive intervention, whereas those with no angiographic CAD are treated less aggressively. We hypothesized that stratifying individuals by PRS after coronary artery angiography would identify individuals at increased risk of mortality, even after accounting for traditional risk factors and extent of angiographic CAD.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure, without approval from the University of Pennsylvania Institutional Review Board.
The study was approved by the Institutional Review Board of the University of Pennsylvania, and all participants provided written informed consent. Full Methods are available in the in the Data Supplement of the article.
RESULTS

CAD PRS and Angiographic CAD
We focused on a cohort of European ancestry individuals with both genotype and cardiac catheterization results (N=1503). There was a significant, graded increase in traditional risk-factor profiles (increased hypertension, diabetes mellitus, smoking, statin use, and body mass index) associated with increasing burden of angiographic CAD (Table I in the Data Supplement). We investigated whether our genome-wide PRS was associated with extent of angiographic coronary disease (no angiographic CAD versus nonobstructive (<50% stenosis or luminal irregularities) versus obstructive (≥50% stenosis, stent or graft). There was a significant (Fisher exact test, P=0.02) association between PRS quartile and the burden of angiographic disease on coronary angiogram (Table II in the Data Supplement).
To adjust for clinical covariates, we used multinomial logistic regression to examine the effect of a 1 SD change in PRS with the risk of having nonobstructive or obstructive CAD. A 1 SD increase in polygenic risk was associated with increased odds of obstructive angiographic CAD (odds ratio, 1.8; 95% CI, 1.5-2.1; P=2.3×10 -9 ) and nonobstructive CAD (odds ratio, 1.3; 95% CI, 1.05-1.6; P=0.02), adjusting for age at catheterization and sex. These associations were attenuated after additional adjustment for traditional cardiovascular risk factors (hypertension, diabetes mellitus, smoking, body mass index, statin; odds ratio for obstructive CAD, 1.5; 95% CI, 1.2-2.0; P=0.0002; odds ratio for nonobstructive CAD, 1.1; 95% CI, 0.9-1.4; P=0.4).
CAD PRS and Mortality After Coronary Angiography
Individuals who underwent both cardiac catheterization and genotyping were divided into 2 groups based on the CAD PRS. Individuals in the high-PRS (hiPRS) group were younger than low-PRS control subjects (66 years versus 69 years; P=2.1×10 -5 ; Table) . Individuals with hiPRS had similar rates of diabetes mellitus, hypertension, smoking, statin use, total cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, hemoglobin A1c, and extent of angiographic CAD at time of index cardiac catheterization.
To determine whether CAD PRS predicts overall survival post angiography independent of angiographic CAD, we used Cox regression modeling. This analysis included a median follow-up of 4.5 years after index cardiac catheterization. After adjustment for traditional cardiovascular risk factors (smoking, diabetes mellitus, hypertension, statin use, body mass index), extent of angiographic CAD at index catheterization, and genetic principal components, individuals with hiPRS were at significantly elevated risk of all-cause mortality compared with controls (hazard ratio, 1.6; 95% CI, 1.2-2.2; P=0.004; Figure 1 ; Figure Because angiographic findings may alter prevention strategies, we assessed changes in statin use after index angiogram. The proportion of statin users versus nonusers increased at 30 days in all groups (43%, 59%, 84% in the no angiographic, nonobstructive, and obstructive CAD groups, respectively; P<0.01). There was no difference in the proportion of statin use in the hiPRS versus control groups at 30 days (68% versus 69%; P=0.5). Adjusting for statin use at 30 days after angiography rather than statin use at time of index angiogram had no effect on the hazard for mortality.
To further examine the difference in survival between hiPRS and control groups, we stratified individuals based on the extent of angiographic CAD, which has been previously associated with risk of death after cardiac catheterization. 15 After stratifying by extent of angiographic CAD, individuals with no angiographic CAD were at significantly increased risk of all-cause mortality (hazard ratio, 2.4; 95% CI, 1.0-5.5; P=0.04; Figure 2 ; Figure III in the Data Supplement). In individuals with nonobstructive or obstructive CAD by angiography, the associated risk of mortality was of lesser magnitude and did not reach statistical significance (nonobstructive CAD hazard ratio, 1.6; 95% CI, 0.8-3.3; P=0.16; obstructive CAD hazard ratio, 1.4; 95% CI, 0.9-2.2; P=0.10). There was no significant interaction between hiPRS and angiographic extent of disease.
Risk Assessment
To determine the contribution of our PRS on all-cause mortality, we constructed Cox regression models for hiPRS, each traditional risk factor, and angiographic extent of CAD. We compared these models' predictions of 5-year survival using time-dependent area under the receiver-operating curve ( Figure 3) . The model incorporating conventional risk factors, angiographic CAD, and hiPRS best predicted 5-year overall survival, performing significantly better than the current standard-of-care model that incorporates conventional risk factors and angiographic extent of CAD (area under the receiveroperating curve, 0.70; 95% CI, 0.66-0.75 versus 0.65; 95% CI, 0.61-0.70; P=0.001). Similarly, the model incorporating hiPRS had a nominally higher area under the receiver-operating curve (0.69; 95% CI, 0.64-0.73) than models incorporating each conventional risk factor, angiographic extent of CAD, or a model combining conventional risk factors with angiographic CAD.
Finally, we modeled the absolute risk of the primary outcome in individuals with and without hiPRS. Individuals with hiPRS had 22% median 5-year risk of allcause mortality, compared with 13% for individuals in the control group (P<2.2×10 -16 ; Figure IV in the Data 
Supplement]
). This resulted in hiPRS being associated with an 8.1% (95% CI, 6.6%-9.5%) increase in absolute risk of 5-year all-cause mortality, after controlling for traditional risk factors and the results of cardiac catheterization.
DISCUSSION
In this study, we leveraged a large biobank population with genetic information linked to electronic health records to evaluate the use of a PRS to predict survival after coronary angiography. We found that a genomewide PRS was significantly associated with both lifetime diagnosis of CAD, as well as angiographically prevalent disease, consistent with prior studies. 6, 13, 14, 16 We extended these findings to show that an elevated PRS is strongly associated with all-cause mortality after cardiac catheterization. The addition of a PRS also significantly improved the predictive capabilities of the current bestavailable risk stratification modalities.
This study adds to the growing evidence that genetic risk is a strong contributor to both prevalent and incident CAD, independent from traditional cardiovascular risk factors. 10, 13, 14, 17, 18 More recently, genome-wide PRS, which incorporate up to millions of independent variants to improve predictive power, seem to strongly associate with cardiovascular disease risk.
12-14 Consistent with those results, our score comprised of 139 239 variants demonstrated clear associations with lifetime diagnosis of CAD, as well as angiographic extent of CAD. Interestingly, high polygenic risk was associated with similar traditional risk-factor profiles and angiographic burden of disease among individuals with available catheterization data. Notably, though, individuals at high polygenic risk were younger at time of cardiac catheterization. This finding may suggest that lifetime exposure to polygenic risk factors is an important contributor to CAD, as is the case for many monogenic variants which confer either increased risk or protection from coronary disease. [19] [20] [21] [22] [23] [24] Adverse genetics may lower the threshold for developing CAD before the clinical manifestations of traditional risk factors.
We found that after adjustment for traditional risk factors and angiographic extent of CAD, high polygenic risk is associated with a considerable increase in all-cause mortality, with a substantial and clinically significant 8.1% (95% CI, 6.6%-9.5%) absolute risk increase in 5-year mortality after cardiac catheterization. The mechanism behind this association is likely multifactorial. Many of the monogenic variants associated with CAD have known mechanisms that span the range of traditional risk factors like hypertension, hyperlipidemia, obesity, diabetes mellitus, inflammation, and smoking, as well as other cardiometabolic diseases and gene-environment interactions. Number at risk
Figure 1. High polygenic risk scores (hiPRS) is associated with increased risk of all-cause mortality after cardiac catheterization.
Cox regression was performed to assess whether high polygenic risk of coronary artery disease was associated with increased risk of all-cause mortality after cardiac catheterization. Risk of mortality was adjusted for age, sex, hypertension, diabetes mellitus, smoking status, statin use, body mass index, angiographic extent of CAD, and genetic principal components (n=10). Tick-marks represent censoring. HR indicates hazard ratio.
Given the similar traditional risk-factor profile in our cohort between individuals with high polygenic risk and controls, nontraditional risk factors may explain the large difference in mortality. Our finding that hiPRS was a better predictor of 5-year mortality when compared with conventional CAD risk factors or angiography may reflect the power of our PRS to capture both traditional and nontraditional risk. Likewise, despite comparable cross-sectional risk profiles, lifetime exposure to unfavorable genetics may confer additional risk. 28 Current guidelines recommend aggressive secondary prevention strategies for individuals with known coronary disease, and aggressive primary prevention strategies for individuals with conventional risk factors like hyperlipidemia, diabetes mellitus, smoking, and hypertension. 1, 5 Notably, in a stratified analysis based on angiographic extent of disease, individuals with no angiographic CAD but with high PRS remained at significantly elevated risk of all-cause mortality. This result suggests that absence of angiographic CAD is not necessarily a reassuring finding. Furthermore, this result raises the possibility that genetic risk scores may allow for the identification of individuals who may benefit from more aggressive primary prevention in the absence of other identifiable risk factors or evidence of disease. Similarly, although no significant association between hiPRS and mortality was observed in stratified analysis of individuals with nonobstructive or obstructive CAD, these analyses may be underpowered, and a smaller but significant effect between hiPRS and mortality in these individuals should not be excluded based on our findings. Traditional cardiovascular risk factors are highly influenced by healthy lifestyle and medications. Similarly, adherence to a healthy lifestyle, cardiorespiratory fitness, physical activity, and grip strength have all been associated with reductions in risk of incident CAD and cardiovascular death, even in those individuals at highest genetic risk. 10, 17, 18 Our results suggest that incorporating a genome-wide PRS into traditional risk-factor assessment may improve our ability to identify individuals most likely to benefit from aggressive risk-reduction strategies. These results underscore the need for careful application of genetic risk scores. Further validation in large populations from clinically derived biobanks, as well as prospective studies of genetic risk stratification as an adjunct to traditional risk assessment, are warranted.
Our study has several strengths and limitations. First, this study represents a retrospective analysis at a large academic referral center, which may limit its generalizability. However, this focused population allowed us to leverage detailed cardiovascular risk assessment, including traditional risk-factor profiles and coronary angiography, which may not be available in larger cohorts. Although information related to reason for cardiac catheterization, as well as intervention at time of catheterization, was not available, leaving the potential for confounding by indication, angiography is typically performed in individuals with high clinical probability of CAD. Information related to death was obtained from a large national database; however, cause of death was not adjudicated. It is thus possible that our PRS predicts noncardiovascular mortality; however, this seems unlikely given the strong associations with overall CAD. Finally, our results were limited to individuals of European ancestry because summary-level data for genetic risk of CAD in other ancestral populations is lacking. Further study in these populations is strongly warranted.
Overall, after adjusting for traditional cardiovascular risk factors and angiographic extent of CAD, we found that high genetic risk of CAD was associated with substantially elevated risk of all-cause mortality after cardiac catheterization. 
